Breast Examination Center of Harlem Expands Service

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

NEW YORK--Gospel singers, ministers, elected officials, breast cancer survivors, and the president and board of Memorial Sloan-Kettering Cancer Center came to Harlem to celebrate, with music and soul food, the expansion of the Breast Examination Center of Harlem, a center that has screened more than 24,000 women for breast cancer since its opening in 1979.

NEW YORK--Gospel singers, ministers, elected officials, breastcancer survivors, and the president and board of Memorial Sloan-KetteringCancer Center came to Harlem to celebrate, with music and soulfood, the expansion of the Breast Examination Center of Harlem,a center that has screened more than 24,000 women for breast cancersince its opening in 1979.

The center, a program of Memorial Sloan-Kettering with fundingfrom the New York State Department of Health, provides the womenof Harlem with free screenings for breast cancer. Now, as a resultof the expansion, the center is adding cervical cancer screening,and has the equipment and staff to perform 20,000 examinationsa year.

Since opening in 1979, the center has identified nearly 400 womenwith the disease. Of the total, 32% have been diagnosed in theearly stages, a rate much higher than typically found at otherscreening programs in medically underserved communities.

By comparison, only 6% of unscreened breast cancer patients seenat Harlem Hospital over a 20-year period were diagnosed with stageI disease.

The spacious and sunny center, its walls hung with pastel paintingswith a Caribbean theme, has added three mammography units andnew examination rooms. The center, which has a staff of 16, willbe able to double the number of patient visits and accommodatemore personnel, including "patient navigators" who willassist women from the time of diagnosis through resolution.

At the ceremony celebrating the reopening, Harold P. Freeman,MD, director of surgery at Harlem Hospital and medical directorof the center, recalled how the center got started. In 1977, HarlemHospital had done a study showing that of the first 165 breastcancer cases analyzed, half were incurable when they walked inthe door and only 30% were alive after 5 years. "We knewthat we had a very, very serious problem," Dr. Freeman said.

To deal with these problems, the center was opened in January,1979. "The State of New York gave us the space and a yearlygrant; then, in 1980, they brought in one of the most respectedcancer centers in America, Memorial Sloan-Kettering, to carryit to state of the art," he said.

Members of Memorial Sloan-Kettering's Department of Radiologyinterpret the mammography studies performed at the center, andits pathologists will interpret the Pap smears.

"Our involvement in this center is part of our commitmentto the control and cure of cancer," said Memorial Sloan-KetteringPresident Paul Marks, MD. "Early detection is our best hopeto improve cure rates for breast, uterine, and cervical cancers.As we expand this center, we expand Sloan-Kettering's commitmentto women's health."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content